Navigation Links
'Extracellular vesicles' may open new opportunities for brain cancer diagnosis and treatment
Date:4/8/2013

Philadelphia, Pa. (April 8, 2013) The recent discovery of circulating "nano-sized extracellular vesicles" (EVs) carrying proteins and nucleic acids derived from brain tumors may lead to exciting new avenues for brain cancer diagnosis, monitoring, and treatment, according to a special article in the April issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

The review article by Dr. David Gonda from the laboratory of the corresponding author Dr. Clark C. Chen, with contributions from the senior author, Dr. Bob S. Carter of University of California, San Diego, Dr. Fred Hochberg at Massachusetts General Hospital and Dr. Steve Kalkanis of the Henry Ford Hospital brain tumor programs discusses "the biological processes mediated by these EVs and their applications as biomarkers for brain tumor diagnosis, monitoring, and therapeutic development." The researchers add, "Opportunity exists to use EVs as delivery vehicles or immune modulatory tools" for brain cancer treatment.

Nano-Sized EVs Play Role in Cancer Growth and Survival

The authors use the term EVs to refer to various types of "membrane-encapsulated cellular components" released from cells. Microscopic EVstiny even in relation to the cells that produce themhave been isolated from all bodily fluids, including the blood and cerebrospinal fluid of patients with brain tumors. Extracellular vesicles are like nano-sized "bubbles" of material sent out by cells, containing proteins and other cellular materialsincluding nucleic acids that carry genetic information.

So far, researchers have identified three general biological functions of EVs: remodeling and removal of cellular components; elimination of "toxic metabolites or unneeded membrane components" from cells; and intercellular communication, providing a means for transferring proteins or genetic information from one cell to another.

In patients with brain cancer, EVs may also provide a way for tumor cells to alter the microenvironment in which they grow. Different types of EVs may perform functions enabling cancers to grow and spread while evading the immune responses that would target tumor cells for destruction.

Could EVs Be Used for Cancer Detection and Treatment?

Scientific efforts to understand EVs and their functionsin normal physiology as well as in cancers and other disease statesare just getting started. But researchers envision new opportunities for the development of biomarkers for diagnosis and monitoring of brain cancers, as well as possible new treatment strategies based on EVs.

Approaches based on identifying specific proteins and genetic material carried by EVs could be useful in identifying brain cancers, and monitoring their status over time. For example, EVs might be used in identifying specific mutations of the IDH1 gene, recently linked to a type of brain cancer called glioblastoma multiforme. Corresponding author Dr. Chen noted in correspondence that "A large consortium effort among neurosurgeons and neuro-oncologists is emerging to assess the clinical utility of the basic science findings highlighted in our review. We anticipate that the next several years will yield important information as teams of scientists and clinicians work to study these questions."

Further studies of the function of EVs may open at least three directions for brain cancer treatment. Treatments could be devised to inhibit the secretion and uptake of tumor-related EVs, which might interfere with their ability to grow or spread. New approaches to immunotherapy might be developed, using EVs to stimulate immune responses against tumor cells. It might also be possible to engineer EVs to serve as "delivery vehicles" to target drugs directly to cancer cells.

"Enhanced secretion of EVs by tumors offers an opportunity to detect tumor-specific genetic material as biomarkers for diagnostic or therapeutic monitoring," the authors conclude. While extensive research is still needed to understand how EVs work and how they can be exploited for specific uses, they write, "Awareness of these developments should augment the armamentarium available to oncology-dedicated neurosurgeons."


'/>"/>

Contact: Connie Hughes
connie.hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health
Source:Eurekalert

Related medicine news :

1. Notre Dame researchers paper examines the biology of tumor-derived microvesicles
2. Laser Die-Cutting Creates New Opportunities for Acrylic Photo Gifts
3. General Plastics Announces Global Distribution Opportunities
4. Lice Happens Now Offering "Lousy" Franchise Opportunities
5. MMS Group Explores New Opportunities for Placing Healthcare Contractors
6. Newly Published by Atlantic Information Services — Dual Eligibles: The New Growth Opportunities Ahead for Health Plans
7. Dr. Kent Stobaugh Retiring from Oral & Maxillofacial Surgeons to Pursue Different Opportunities: SA4i Emphasizes Significant Contributions to People’s Lives
8. ProvidaStaff,LLC Reports on Increased Travel Therapy & PRN Career Opportunities During The Holidays
9. HCOs find risks & opportunities in quest for reduced costs & improved quality
10. STOP Obesity Alliance new state-level members share obstacles, opportunities in addressing obesity
11. Dotcomsecrets is Offering New Opportunities to People Who Want to Become Expert in Localized Internet Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology: